Amanta Healthcare share price
NSE: AMANTABSE: 544502Pharmaceuticals & BiotechnologySmall Cap
Last close ₹163.07down ₹1.81 (1.10%)BSE ₹163.20
Share price at the NSE close on 23 Oct 2026. Previous close ₹164.88.
52-week range of traded prices to 23 Oct 2026
₹92.00Low, 16 Mar 2026₹209.95High, 10 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹633 Cr1,889th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 5 Aug 2026
- 43.1
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹2.63 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 36.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 2.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record. The filing of 5 Aug 2026
- 6.7%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹2.63 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 7.9%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 5 Aug 2026
- 9.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 1.06
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 1,21,12048.9% delivered
Results
Standalone; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 5 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹69 Crdown 10.64%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹3.31 Crdown 40.15%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 4.8%
Revenue by year
Net profit by year, a loss in red
| ₹ crore | Jun 2025Filed 27 Sep | Sep 2025Filed 27 May | Dec 2025Filed 29 May | Mar 2026Filed 29 May | Jun 2026Filed 5 Aug |
|---|---|---|---|---|---|
| Revenue | 65.3 | 70.9 | 74.5 | 77.0 | 68.8 |
| Net profit | 3.5 | 1.2 | 4.6 | 5.5 | 3.3 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 5.4% | 1.7% | 6.2% | 7.2% | 4.8% |
Standalone. The 5 quarters from Jun 2025, the first on record. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, Manufacture of pharmaceuticals, medicinal chemical and botanical products, which carries all its revenue.
Valuation
Today, against the company's own history. Dividend yield is not shown: no dividend in the years on record.PE ratio and valuation history
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 71% of 235 trading days since Nov 2025.
LowestHighest
Its median2.4Industry median2.8
Mutual funds holding it
1 fund disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before.
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 1
| Fund | |||
|---|---|---|---|
 Bandhan Small Cap FundBandhan Mutual Fund | 19,87,784 | 0.11% | ₹37.8 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Amanta Healthcare in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Anuh PharmaANUHPHR | 768 | 17.4 | 2.2 | 11.7 | +9.7% | −4.3% | 13.0% | 15.2% | 1.96% |
 Kilitch Drugs (India)KILITCH | 707 | 23.5 | 2.5 | 21.5 | +14.0% | – | 12.5% | 8.9% | 0.00% |
 Valiant LaboratoriesVALIANTLAB | 698 | 43.6 | 2.2 | 22.1 | +89.6% | +12,324.8% | 5.9% | 7.0% | 0.00% |
 Zim LaboratoriesZIMLAB | 677 | 183.2 | 2.3 | 26.8 | +7.6% | −60.6% | 1.3% | 1.8% | 0.00% |
 WanburyWANBURY | 624 | 11.2 | 4.3 | 8.4 | +3.6% | +30.0% | 54.9% | 23.3% | 0.00% |
 Influx HealthtechINFLUX | 595 | 28.9 | 5.9 | – | – | – | 20.4% | – | 0.00% |
 TranschemTRANSCHEM | 513 | 76.2 | 6.1 | – | −100.0% | +47.5% | 8.3% | −4.9% | 0.00% |
 KRM AyurvedaKRMAYURVED | 508 | – | 4.4 | – | – | – | – | – | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
Sep 2026
Amanta Healthcare share price by year
Each calendar year to 2025.Amanta Healthcare share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 109.06 | – | 148.72 | 99.07 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2025 is from its first session, 9 Sep 2025.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 165.25 | 168.57 | 155.00 | 163.07 | 161.04 | 1,21,120 | 48.9% |
| 22 Oct 2026 | 162.50 | 171.00 | 154.03 | 164.88 | 164.03 | 1,40,301 | 48.3% |
| 21 Oct 2026 | 168.00 | 169.67 | 151.71 | 160.18 | 159.20 | 3,15,289 | 57.7% |
| 19 Oct 2026 | 179.51 | 182.40 | 163.00 | 164.63 | 170.55 | 1,32,496 | 78.7% |
| 16 Oct 2026 | 189.70 | 189.70 | 181.15 | 183.41 | 184.07 | 33,257 | – |
| 15 Oct 2026 | 188.49 | 192.00 | 184.00 | 188.53 | 187.06 | 48,723 | – |
| 14 Oct 2026 | 174.70 | 184.27 | 174.00 | 184.27 | 181.40 | 34,196 | – |
| 13 Oct 2026 | 182.34 | 182.34 | 173.11 | 175.50 | 175.93 | 74,838 | – |
| 12 Oct 2026 | 188.78 | 193.49 | 179.16 | 182.22 | 183.69 | 68,480 | – |
| 9 Oct 2026 | 196.00 | 196.00 | 186.93 | 187.42 | 188.30 | 78,810 | – |
Prices in ₹ per share as traded, not adjusted.
Company details
- Legal name
- Amanta Healthcare Limited
- NSE symbol
- AMANTA
- BSE code
- 544502
- ISIN
- INE084K01015
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Sep 2025
- Face value
- ₹10
- CIN
- L24139GJ1994PLC023944
- Corporate identity number, the registrar of companies' code for it